Cyclodextrin has conflicting actions on autophagy flux <i>in vivo</i> in brains of normal and Alzheimer model mice
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
The three-model screen
all 1,000 screened works →All three models called this out of scope.
Cyclodextrin effects on autophagy in mouse brains; preclinical neuroscience.
The work studies autophagy and cyclodextrin effects in disease models, not research itself.
Biomedical study of cyclodextrin effects on autophagy in AD mice; domain neuroscience.
Abstract
2-hydroxypropyl-β-cyclodextrin (CYCLO), a modifier of cholesterol efflux from cellular membrane and endo-lysosomal compartments, reduces lysosomal lipid accumulations and has therapeutic effects in animal models of Niemann-Pick disease type C and several other neurodegenerative states. Here, we investigated CYCLO effects on autophagy in wild-type mice and TgCRND8 mice-an Alzheimer's Disease (AD) model exhibiting β-amyloidosis, neuronal autophagy deficits leading to protein and lipid accumulation within greatly enlarged autolysosomes. A 14-day intracerebroventricular administration of CYCLO to 8-month-old TgCRND8 mice that exhibit moderately advanced neuropathology markedly diminished the sizes of enlarged autolysosomes and lowered their content of GM2 ganglioside and Aβ-immunoreactivity without detectably altering amyloid precursor protein processing or extracellular Aβ/β-amyloid burden. We identified two major actions of CYCLO on autophagy underlying amelioration of lysosomal pathology. First, CYCLO stimulated lysosomal proteolytic activity by increasing cathepsin D activity, levels of cathepsins B and D and two proteins known to interact with cathepsin D, NPC1 and ABCA1. Second, CYCLO impeded autophagosome-lysosome fusion as evidenced by the accumulation of LC3, SQSTM1/p62, and ubiquitinated substrates in an expanded population of autophagosomes in the absence of greater autophagy induction. By slowing substrate delivery to lysosomes, autophagosome maturational delay, as further confirmed by our in vitro studies, may relieve lysosomal stress due to accumulated substrates. These findings provide in vivo evidence for lysosomal enhancing properties of CYCLO, but caution that prolonged interference with cellular membrane fusion/autophagosome maturation could have unfavorable consequences, which might require careful optimization of dosage and dosing schedules.
Stored with the screening record, where it is evidence for the labels above.
The record
- Venue
- Human Molecular Genetics
- Topic
- Autophagy in Disease and Therapy
- Field
- Medicine
- Canadian institutions
- —
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Institute of Child Health and Human DevelopmentAlzheimer's AssociationNational Institute of Neurological Disorders and StrokeNational Institute on AgingUniversity of Alberta
- Keywords
- AutophagyLysosomeBiologyAutophagosomeCathepsin BCell biologyCathepsin DSequestosome 1NeurodegenerationProteostasisCathepsinTauopathyAmyloid precursor proteinPopulationBiochemistryAlzheimer's diseaseInternal medicineMedicineEnzyme
- Has abstract in OpenAlex
- yes